Ariad Pharmaceuticals Stock Gains Momentum On Iclusig Prospect (NASDAQ:ARIA)

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA)

With Crude Oil sectors down and the Dow Jones Industrial Average Up +9.83 points above 16,000, let’s check out Ariad Pharmaceuticals ticker symbol ARIA. Ariad Pharmaceuticals is an integrated global oncology company specializing in areas of cancer with innovative breakthrough medicines. The Company has surged +21.14% Up 0.59 with colossal interest in the finacial markets concerning that this Company has generated over 23.7 million shares in play Friday November 22, 2013 10:41AM EST. So what’s hot about Ariad Pharmaceuticals stock you ask?

The Company (www.ariad.com) announced a positive opinion by the European Medicines Agency on the ongoing accessiblity of Iclusig in Patients with Leukaemias. Iclusig is used to treat a type of blood cancer called chronic myeloid leukemia, or Philadelphia chromosome positive acute lymphoblastic leukemia. The medicine interferes with process of some cancer cells increasing in physical size. The global market in reference to cancer therapies is predicted to rake in around $110.6 billion by the end of 2013. From this prospective Iclusig assumptionally provides a great service safely guiding patients and professional health medicalist, as they consider using this products treatment options globally.

****

Cardiome Pharma Corp. (NASDAQ:CRME)

As long as we’re on the subject of Pharmaceutical stocks, take a look at Cardiome Pharma Corp. ticker symbol CRME. Cardiome Pharma specializes in bio pharmaceuticals  areas concerning innovative therapeutics targeted at improving the health of patients troubled from heart disease around the world.  In the financial market, the Company  has surged +14.21% Up 0.83  generating over 500K shares in play Friday November 22, 2013 11:34AM EST. The story concerning this Company (www.cardiome.com) is a hot product and it’s ability to expand.

The product BRINAVESS™,  contains the active substance vernakalant hydrochloride. BRINAVESS™ works by changing irregular or fast heart beat to a normal. The global market concerning cardiovascular diseases is predicted to rake in around $9.2 billion Euro or $12.4 billion U.S. by the end of 2013. The ace with a kicker is Correvio. Cardiome Pharma completed an acquisition for Correvio, which is headquartered Geneva, Switzerland. In layman’s terms, this broadens BRINAVESS™ availability while maximizing product prediction capacity in the global market.   

**** 

Crown Equity Holdings Inc. (OTCMKTS:CRWE)

While the financial market analyst speculate what Janet Yellen will mean for the Wall Street, let’s focus our attention towards Crown Equity Holdings Inc. ticker symbol CRWE. Crown Equity Holdings specializes in a vast array of network services in reference to website distribution and development, investor relations, human resources, video streaming through CRWETube (http://crwetube.com/), and advertisement. Crown Equity Holdings stock has gained +718.18% positive traction in the stock market concerning its 52 week low. If we were in a game of poker, the chip up would be the Company (http://crownequityholdings.com) founding iB2B Global.

iB2B Global is a global B2B trade online directory for wholesale and retailers. To view iB2B Global short form business plan visit URL(http://crownequityholdings.com/extras/iB2BGlobal_business_plan.pdf) via the internet. iB2B Global expects to achieve $10 to $15 million in total EBITA by the end of their third year. Analyst could predict that Crown Equity Holdings is in a great position concerning investor returns, as the U.S. tech market expects to grow around 7.5% by the end of 2013. The United States ecommerce market expects to make around $262.3 billion in sales this year concerning internet conducted transactions.

Remember: Always do your homework and consult your own financial professional.

Read Full Disclaimer at http://crweselect.com/disclaimer/